Actualités

West Pharmaceutical Services has surged 38.1% since March-end as HVP demand, GLP-1 growth and productivity gains fuel the rally.

West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

WST's faster HVP growth, wider margins and stronger earnings outlook support the bull case, but its premium valuation leaves less room for error.

West Pharmaceutical's Q2 beat, faster HVP growth and wider margins drove a higher 2026 outlook, strengthening its earnings case.

NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.

RadNet tops Q2 estimates as advanced imaging and Digital Health growth accelerate, prompting a higher 2026 Imaging Center outlook.

INGN's Q2 revenues rise 3% as international sales climb 14.8%, but U.S. weakness led it to cut its 2026 revenue outlook.

IRTC posts 20.1% revenue growth, margin expansion and a higher 2026 outlook while advancing innovation and its Vital Connect acquisition.

AMN Healthcare's Q2 EPS jumps 158% as revenues rise 2.3%, helped by travel nurse, allied and search growth plus labor disruption activity.

LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.

McKesson shares rise after fiscal Q1 earnings and revenues beat estimates, powered by specialty growth, as the company raises its 2027 EPS outlook.

Cencora's fiscal Q3 EPS beats estimates as broad segment growth lifts profit, prompting a higher 2026 outlook despite a slight revenue miss.

Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.

INSP beats second-quarter estimates, raises its 2026 outlook and sees shares jump despite U.S. reimbursement pressures and lower revenues.

In late July 2026, West Pharmaceutical Services reported second-quarter 2026 results showing higher sales and earnings than a year earlier, raised its full‑year 2026 revenue guidance, and completed US$454.28 million of share repurchases under its February 2026 buyback program. The company also issued third‑quarter revenue guidance, highlighted momentum in higher‑value Proprietary Products for biologics and biosimilars, and affirmed a US$0.22 quarterly dividend. Against this backdrop, we’ll...

West Pharmaceutical Services has been on fire lately. In the past six months alone, the company’s stock price has rocketed 43%, reaching $339.52 per share. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.

Merit Medical's Q2 adjusted EPS jumps 18% as revenues rise 9.5%, margins expand and 2026 guidance increases after broad product growth.

Baxter beats second-quarter earnings and revenue estimates, posts broad-based segment growth and raises its 2026 outlook despite margin pressure.

GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.

GE HealthCare beats second-quarter estimates as revenues rise 5.7%, orders climb 11.1% and backlog hits a record $23.9 billion.

MNST, CRS and USIO highlight Zacks strategies that outperformed amid a volatile market.

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.

WST tops Q2 earnings and revenue estimates, lifts its 2026 EPS outlook and sees shares surge as high-value products fuel strong growth.

Healthcare products company West Pharmaceutical Services (NYSE:WST) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 13.8% year on year to $872.3 million. Guidance for next quarter’s revenue was better than expected at $827.5 million at the midpoint, 0.8% above analysts’ estimates. Its non-GAAP profit of $2.37 per share was 13.9% above analysts’ consensus estimates.

WST heads into Q2 earnings with expectations for revenue and EPS growth, backed by demand for biologics and GLP-1 components plus manufacturing gains.

MMSI vs. WST: Which Stock Is the Better Value Option?

SYK launches Mako RPS, expanding into handheld robotics for total knee replacement and broadening access to robotic-assisted orthopedic procedures.

DHR heads into Q2 earnings with bioprocessing and diagnostics strength, but rising costs and debt could pressure profitability.

SNN launches the LYNX COBLATION Laryngeal Wand, combining precise dissection, rapid debulking and hemostasis for airway procedures.

ANGO's Q4 FY26 revenues rise 8% as Med Tech surges, while its adjusted loss beats estimates and FY27 sales guidance tops consensus.